Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC

Author:                  

Publisher: Spandidos Publications

ISSN: 1019-6439

Source: International Journal of Oncology, Vol.41, Iss.6, 2012-01, pp. : 1943-1949

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content